alexa Gaps And Bridges In Evolving Rationale Of COPD Pharmacotherapy

Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Recommended Journals

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Chronic Obstructive Pulmonary Disease
May 29-31, 2017 Osaka, Japan

Amnon P Ariel
HaEmek Medical Center, Israel
Posters & Accepted Abstracts: J Pulm Respir Med
DOI: 10.4172/2161-105X-C1-025
COPD pharmacotherapy aims at treatable traits of a disease previously considered irreversible. The evolution of COPD pharmacotherapy follows two different paths, related to the British and Dutch hypotheses, respectively. The first path seeks “COPD specific” traits, e.g., ameliorating air-trapping and combating non-eosinophilic inflammation, currently represented by the long acting bronchodilators and PDE4 inhibitors. The second path is a “copy-paste” approach utilizing asthma therapeutics in COPD, best represented by the current overuse of inhaled corticosteroids (ICS) to treat “COPD at-large”. In the past, short-acting bronchodilators were used to treat COPD with modest effectiveness until the advent of long-acting beta agonists (LABA). Early clinical research of ICS in COPD showed some symptomatic improvement with a questionable effect on exacerbations without affecting FEV1 decline or mortality. The availability of ICS-LABA combination inhales and the development of long-acting antimuscarinics (LAMA) set the stage for debating which pharmacotherapy is better for moderate-severe COPD. The COPD mega-trials, ToRCH and UPLIFT failed to achieved statistical significance in their primary outcomes. However, these studies demonstrate the salutary effects of LABA and LAMA on COPD outcome measures including exacerbations. Factorial analysis of ToRCH contributed to understanding the limited role of ICS, weighed against the increased risk of pneumonia. In the SUMMIT study, ICS-LABA failed to decrease cardiovascular mortality in moderate COPD. While “systemic-COPD” affects comorbidity, ICS-LABA treatment failed to show effectiveness in this regard. The recent definition of Asthma COPD overlap syndrome along with the, yet untested, recommendation for the use of ICS-LABA in these patients deserves further consideration. GOLD 2017 prefers LAMA to LABA as the first line long-acting bronchodilator, and recommends using LAMA-LABA combination before ICS in exacerbation prone COPD. An argument can be made for better definition at diagnosis (FEV1/FVC < LLN threshold) as well patient phenotyping aiming to improve the therapeutic success.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version